Posted by Yesterday, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that Chief Executive Officer John Higgins issued a letter to Ligand’s Captisol® customers.
The communication mostly addresses Ligand’s plans to overcome the sudden increase in the global need for Captisol (sulfobutyl-ether-beta-cyclodextrin, SBECD) due to its use as a critical excipient in Gilead’s remdesivir formulation.